Menu

Biosimilars/News

48 MD002137

Heparin biosimilar to be marketed in Canada

Biosimilars/News | Posted 30/08/2019

Canadian pharmaceuticals firm Valeo Pharma Inc has been given the rights to market a biosimilar version of low molecular weight heparin (LMWH), which is used to prevent blood clots in a range of conditions.

Trastuzumab Herceptin V13D12

Trastuzumab biosimilar to be distributed by Mundipharma

Biosimilars/News | Posted 30/08/2019

Singapore-based Prestige BioPharma’s (Prestige) trastuzumab biosimilar Tuznue (HD201) will be distributed in selected European markets exclusively by UK-based Mundipharma International (Mundipharma) and its independent associated companies. Tuznue is a biosimilar of Roche’s Herceptin (trastuzumab) which is used to treat patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer, HER2-overexpressing metastatic gastric cancer or gastroesophageal junction adenocarcinoma.

Australia flag V13C29

Mylan launches first trastuzumab biosimilar in Australia

Biosimilars/News | Posted 23/08/2019

Global generics firm Mylan NV (Mylan) and collaborating Indian pharmaceuticals giant Biocon Ltd (Biocon) have announced the launch of the first trastuzumab biosimilar in Australia. The drug can be used to treat breast and stomach cancers and will be marketed as Ogivri.

Anaemia 2 V13J18

Samsung Bioepis starts phase III trial for eculizumab copy biological

Biosimilars/News | Posted 23/08/2019

Korea-based Samsung Bioepis (Samsung and Biogen’s joint venture) is carrying out a phase III clinical trial for a copy biological of Soliris (eculizumab), made by Alexion Pharmaceuticals (Alexion).

02 AA010638

Korean firms to launch biosimilars in Japan despite trade tensions

Biosimilars/News | Posted 16/08/2019

Despite increasing trade tensions between Japan and Korea, two Korean firms have confirmed that they intend to move ahead with the launch of their darbepoetin alfa biosimilars in Japan in the second half of 2019.

Approved-V13G05

FDA approves adalimumab biosimilar Hadlima

Biosimilars/News | Posted 16/08/2019

Korea-based biosimilars maker Samsung Bioepis (Samsung and Biogen’s joint venture) announced on 24 July 2019 that it had received approval from the US Food and Drug Administration (FDA) for its adalimumab biosimilar (SB5).

Application V15a16

EMA accepts first application for Chinese-made biosimilar HLX02

Biosimilars/News | Posted 09/08/2019

China-based Shanghai Henlius Biotech (Henlius) announced on 21 June 2019 that the regulatory submission for its proposed trastuzumab biosimilar (HLX02) had been accepted by the European Medicines Agency (EMA).

Review committee V15a16

Rituximab copy biological accepted for review in China

Biosimilars/News | Posted 09/08/2019

China’s National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), has accepted an application for approval of rituximab copy biological IBI301.

Biologicals 1 V13D05

FDA approves rituximab biosimilar Ruxience

Biosimilars/News | Posted 02/08/2019

US-based pharma giant Pfizer announced on 23 July 2019 that it had received approval from the US Food and Drug Administration (FDA) for its rituximab biosimilar (PF 05280586).

Insulin 1 V13C03

Lannett starts phase I trial for insulin glargine biosimilar in South Africa

Biosimilars/News | Posted 02/08/2019

US generics maker Lannett Company (Lannett) announced on 5 June 2019 that it had started a phase I clinical trial of its candidate insulin glargine biosimilar.